Steffan Ho
Vice President & Head of Translational Oncology Pfizer
Seminars
Tuesday 3rd February 2026
Transforming Therapeutic Frontiers: Expert Insights on Novel Epigenomic Biomarkers
6:00 pm
Discover how biopharma researchers and clinical oncologists are harnessing the power of novel epigenomic biomarkers to pinpoint the right patients most likely to benefit from your therapy refining your therapeutic strategies and ultimately bringing more effective medicine to the patients who need them.
Wednesday 4th February 2026
Liquid Biopsies in Drug Development: Where They Add Value Today & What Still Needs Work
2:20 pm
- Where liquid biopsies are currently delivering the most value across the drug development lifecycle, and where teams remain cautious
- What are the key practical challenges of integrating liquid biopsy endpoints into clinical development programs
- What needs to change, technically, operationally, or regulatorily, to enable broader and more confident adoption
Wednesday 4th February 2026
Evening Engager, Hosted by Foundation Medicine
7:05 pm
This session will bring together precision medicine experts to discuss how the latest generation of biomarkers are driving smarter trial enrollment and monitoring.
Enjoy dinner, networking, and a panel discussion on opportunities for emerging biomarkers to impact clinical trial design.
Wednesday 4th February 2026
Confronting Complexity: Defining the Next Decade of Liquid Biopsy in Precision Oncology
9:30 am
- Confronting the translational hurdles that limit liquid biopsy adoption in drug development, from tumor heterogeneity and assay sensitivity to cost and trial feasibility
- Integrating emerging technologies such as methylation profiling and AI with the rigor required for clinical validation in oncology trials
- Defining how pharma decision-making will shape the path from exploratory assays to scalable, routine tools that deliver real patient impact
